Michelle Ross, StemPoint Capital CIO and Novo Nordisk shareholder, joins CNBC’s ‘Closing Bell’ to discuss the criticism Novo has faced around high drug prices, the potential earnings impact if prices come down, and more.
Share
Michelle Ross, StemPoint Capital CIO and Novo Nordisk shareholder, joins CNBC’s ‘Closing Bell’ to discuss the criticism Novo has faced around high drug prices, the potential earnings impact if prices come down, and more.